May i also add, there seems to be [within some groups of people] a general assumption that positive outcome of vaccine for covid19 is a given and that it's just a matter of going through the development process. History provides different guidance. The journey to develop a world-beating covid19 vaccine is open season atm with many hurdles to jump. Probablity ans history suggests, with the exception of fast-tracking a safe vaccine with moderate benefits [pushed forward by political will] a genuine world-beating vaccine [vaccines] will take time and a vast array of knowledge from multiple experts. And, while all the pharma plough their cash into development, Open Orphan will continue to generate profitable income regardless of outcome. Open Orphan is at the beginning of its journey [covid and non covid].
Yep, nothing abnormal about a retest given recent price movements. Tricky for traders or short term investors because price could have easily taken a momentary jump to 16/17 - and if conicided with news - edged even further. Company guidance hasn't changed. Last couple of days price movement has sent a flare alerting investors to future price movement. Glass half full thinking says 13.15p is not 11.15p ;)
RE: final thought - technical resistence14 Jul 2020 10:24
I tried cutting the grass two weeks ago, only for the brake cable on the Stiga to snap leading me to take a chunk out of the apple tree. And, no, the share price didn't go up. I wont be putting weeding to the test either.
Developing a 'working' version of covid19 is what hVIVO are attempting to do. Without it, they cannot develop [or sell] a challenge study for covid19. Adrian Wildfire is yet another specialist in this area. CF has hired extra talent to achieve this aim while at the same time eliminating all competition.
Also, when i use the word 'hired' i'm using Cathal's phrasing, not mine.
Melbourne and the non-yielding covid virus07 Jul 2020 09:37
From midnight tomorrow, metropolitan Melbourne and Mitchell Shire, north of Melbourne, will return to stage 3 restrictions for the next six weeks. Four reasons to leave home: shopping for supplies, compassionate care, exercise and for work or study.
Further supports my guidance on a continued need to push forward with covid and respiratory illness vaccines and medicines. Orph remains firmly inline to benefit from both, and more besides.
Deepjoy, we need a nice short, sharp shock to the price to flesh out the remaining low-hanging investors and force them into capitulation. Soon enough we'll be left with a company heading in the right direction within a cash-backed sector with only buyers remaining.